- Home
- SEVN vs ENTA Comparison
SEVN vs ENTA Comparison
Compare SEVN & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- ENTA
- Stock Information
- Founded
- SEVN 1986
- ENTA 1995
- Country
- SEVN United States
- ENTA United States
- Employees
- SEVN N/A
- ENTA N/A
- Industry
- SEVN Real Estate Investment Trusts
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- ENTA Health Care
- Exchange
- SEVN Nasdaq
- ENTA Nasdaq
- Market Cap
- SEVN 173.7M
- ENTA 160.3M
- IPO Year
- SEVN N/A
- ENTA 2013
- Fundamental
- Price
- SEVN $12.85
- ENTA $7.89
- Analyst Decision
- SEVN Strong Buy
- ENTA Buy
- Analyst Count
- SEVN 3
- ENTA 4
- Target Price
- SEVN $14.75
- ENTA $18.00
- AVG Volume (30 Days)
- SEVN 48.7K
- ENTA 181.3K
- Earning Date
- SEVN 07-28-2025
- ENTA 08-04-2025
- Dividend Yield
- SEVN 10.89%
- ENTA N/A
- EPS Growth
- SEVN N/A
- ENTA N/A
- EPS
- SEVN 1.15
- ENTA N/A
- Revenue
- SEVN $30,074,000.00
- ENTA $64,462,999.00
- Revenue This Year
- SEVN $7.45
- ENTA N/A
- Revenue Next Year
- SEVN $1.12
- ENTA $0.48
- P/E Ratio
- SEVN $11.18
- ENTA N/A
- Revenue Growth
- SEVN N/A
- ENTA N/A
- 52 Week Low
- SEVN $10.18
- ENTA $4.09
- 52 Week High
- SEVN $14.66
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- SEVN 64.41
- ENTA 67.33
- Support Level
- SEVN $11.78
- ENTA $6.95
- Resistance Level
- SEVN $12.77
- ENTA $8.23
- Average True Range (ATR)
- SEVN 0.28
- ENTA 0.40
- MACD
- SEVN 0.08
- ENTA 0.00
- Stochastic Oscillator
- SEVN 78.26
- ENTA 75.11
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.